Last month, the professional group updated its stance, saying it had growing concerns over what it calls a «lack of clinical oversight» in the use of medical marijuana if pharmacies don't play a «front - line role» in providing access to the drug.
And the defiant stance actually may have boosted the drug maker's image at a time when Americans are skeptical about the pharmaceutical industry over high drug prices.